Evidence map›Paper›PMID 35783512›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2022

Research on the Mechanism of Asperosaponin VI for Treating Recurrent Spontaneous Abortion by Bioinformatics Analysis and Experimental Validation.

Bo Xia, Peng Zhang, Yuling Lai, Shichao Cui, Zhenyue Chen, Qingying Yu, Haiwang Wu, Lihua Zeng, Baozhen Xie, Jingwei Li and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Bo XiaGuangzhou University of Chinese Medicine, Guangzhou 510405, China.
Peng ZhangGuangzhou University of Chinese Medicine, Guangzhou 510405, China.ORCID https://orcid.org/0000-0003-1777-3790
Yuling LaiGuangzhou University of Chinese Medicine, Guangzhou 510405, China.
Shichao CuiGuangzhou University of Chinese Medicine, Guangzhou 510405, China.
Zhenyue ChenGuangzhou University of Chinese Medicine, Guangzhou 510405, China.
Qingying YuGuangzhou University of Chinese Medicine, Guangzhou 510405, China.
Haiwang WuThe First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Lihua ZengGuangzhou University of Chinese Medicine, Guangzhou 510405, China.
Baozhen XieGuangzhou University of Chinese Medicine, Guangzhou 510405, China.
Jingwei LiGuangzhou University of Chinese Medicine, Guangzhou 510405, China.
Huimin ZhangGuangzhou University of Chinese Medicine, Guangzhou 510405, China.
Songping LuoThe First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, China.ORCID https://orcid.org/0000-0002-6804-4216
Jie GaoThe First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, China.ORCID https://orcid.org/0000-0001-6934-6163
Guangzhou University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Asperosaponin VI (AS6), as the quality marker of

Identifiers

PMID35783512
PMCPMC9246589
OpenAlexW4283387025

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.